This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...

The review emphasizes how breakthroughs in understanding the molecular mechanisms of cell cycle regulation have paved the way for the development of targeted anti-cancer agents. Notably, inhibitors of ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.